Novo Nordisk tackles outcomes and affordability with pilot tying copays to adherence

In a new approach to the pricing and payer issues beleaguering pharma in general and diabetes drugmakers in particular, Novo Nordisk has teamed up on a project that puts patients with diabetes to work earning drug discounts for good behavior. The Danish drugmaker is working with Sempre Health on a pilot program that works through payers to offer patients discounts on their prescriptions, provided they reach particular goals. Those goals include some familiar, apparently simple ones, such as filling prescriptions on time and taking drugs as prescribed. But as drugmakers and payers both know, getting patients to do so isn't simple at all. And in return, the program would offer patients incentives such as lower copays.